Moderna shares crash after disappointing quarterly results - financial expert gives buy recommendation

Moderna verzeichnete im vergangenen Quartal einen Verlust je Aktie von 9,53 Dollar, was deutlich höher war als von den Analysten erwartet. Diese hatten nur mit einem Verlust von 1,93 Dollar gerechnet. Der Ausblick des Unternehmens enttäuscht ebenfalls – die Aktie des Impfstoffherstellers stürzt ab.

For the full year, Moderna forecasts sales of 50 million doses of the corona vaccine, which will lead to revenue of just six billion dollars. The company had previously expected six to eight billion dollars. Moderna also expects sales of around 50 million cans next year.

Although the share price had temporarily fallen by 18 percent, it has now recovered from its lows and is currently only seven percent in the red.

UBS's buy recommendation is likely to have provided a boost. According to analyst Eliana Merle, the vaccine manufacturer implemented more than expected. However, the reduced targets for 2023 and the outlook for 2024 are disappointing. She continues to name a price target of $178.

Moderna's share price is currently at $72, which is its lowest level since November 2020. The title recently fell below the AKTIONÄR stop price.